• News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·EKSO
Share

Ekso Bionics Holdings Inc Stocks

$ 11.8Last Updated 15.05.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 40.51M

$ 11.8
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

01.04.2026 13:20

10 robotics stocks with big returns so far in 2026

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of EKSO is 9.5 and suggests 19% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.05.2026 17:18

Main in small-caps: BuzzFeed deal, bets on AI boom, forecast from BNP Paribas AM

16.05.2026 13:01

Highlights of the week: Trump in China, Cerebras IPO, UK crisis

16.05.2026 04:20

US inflation could soar to 6%, economists have allowed. Their forecast has been halved

16.05.2026 03:33

Ford has its worst collapse in 15 months after rallying 20%. It's even been called a meme stock

16.05.2026 02:27

The stock market approached its highest valuation in history - the days of the dot-com bubble

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026